A drug repurposing screen reveals dopamine signaling as a critical pathway underlying potential therapeutics for the rare disease DPAGT1-CDG
PLOS Genetics · 2024
DOI: 10.1371/journal.pgen.1011458 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Genetics, 2024. Verfasst von Hans M Dalton und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, Utah, United States of America. Hauptthemen laut MEDLINE: Drug Repositioning, Congenital Disorders of Glycosylation, Dopamine, Signal Transduction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NICHD NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
DPAGT1-CDG is a Congenital Disorder of Glycosylation (CDG) that lacks effective therapies. It is caused by mutations in the gene DPAGT1 which encodes the first enzyme in N-linked glycosylation. We used a Drosophila rough eye model of DPAGT1-CDG with an improperly developed, small eye phenotype. We performed a drug repurposing screen on this model using 1,520 small molecules that are 98% FDA/EMA-approved to find drugs that improved its eye. We identified 42 candidate drugs that improved the DPAGT1-CDG model. Notably from this screen, we found that pharmacological and genetic inhibition of the dopamine D2 receptor partially rescued the DPAGT1-CDG model. Loss of both dopamine synthesis and recycling partially rescued the model, suggesting that dopaminergic flux and subsequent binding to D2 receptors is detrimental under DPAGT1 deficiency. This links dopamine signaling to N-glycosylation and represents a new potential therapeutic target for treating DPAGT1-CDG. We also genetically validate other top drug categories including acetylcholine-related drugs, COX inhibitors, and an inhibitor of NKCC1. These drugs and subsequent analyses reveal novel biology in DPAGT1 mechanisms, and they may represent new therapeutic options for DPAGT1-CDG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, Utah, United States of America.
ORCID-Profile: Hans M Dalton, Sydney J Peterson, Clement Y Chow
Förderung
- NIGMS NIH HHS
- NICHD NIH HHS
- National Institute of General Medical Sciences
- Primary Children's Hospital Center for Personalized Medicine
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
Zitieren
APA
Dalton, H. M., Young, N. J., Berman, A. R., Evans, H. D., Peterson, S. J., Patterson, K. A., & Chow, C. Y. (2024). A drug repurposing screen reveals dopamine signaling as a critical pathway underlying potential therapeutics for the rare disease DPAGT1-CDG. PLOS Genetics. https://doi.org/10.1371/journal.pgen.1011458
Vancouver
Dalton HM, Young NJ, Berman AR, Evans HD, Peterson SJ, Patterson KA, et al. A drug repurposing screen reveals dopamine signaling as a critical pathway underlying potential therapeutics for the rare disease DPAGT1-CDG. PLOS Genetics. 2024. doi:10.1371/journal.pgen.1011458
BibTeX
@article{Dalton2024,
author = {Dalton, Hans M and Young, Naomi J and Berman, Alexys R and Evans, Heather D and Peterson, Sydney J and Patterson, Kaylee A and Chow, Clement Y},
title = {A drug repurposing screen reveals dopamine signaling as a critical pathway underlying potential therapeutics for the rare disease DPAGT1-CDG},
journal = {PLOS Genetics},
year = {2024},
doi = {10.1371/journal.pgen.1011458}
}
EUVIMED